Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic
Share
Why It Matters
Palisade Bio got permission to test a new medicine for gut disease. This shows their treatment idea passed an important safety check.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.